Clinical Data ACC 2026: sotatercept meta-analysis backs disease-modifying role in PAH Pharmaceutical TechnologyNew data presented at ACC 2026 clarifies sotatercept's role alongside vasodilator-based regimens in PAH patients.Clinical DataCardiovascularRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaceutical Technology New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients. Clinical DataCardiovascularRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Pharma’s Reluctance To Serve Europe To Dodge MFN Drug Pricing Is ChillingNext: Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
